Profile data is unavailable for this security.
About the company
Exagen Inc. is a provider of autoimmune testing and its purpose as an organization is to provide clarity in autoimmune disease decision-making. The Company has developed and is commercializing a portfolio of testing products, under its AVISE brand. It commercially launched its testing product, AVISE CTD, which enables differential diagnosis for patients presenting with symptoms indicative of a variety of connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The comprehensive nature of AVISE CTD allows for the testing of various relevant biomarkers in one convenient blood draw. Included in AVISE CTD is its proprietary AVISE Lupus test, which enables the diagnosis of systemic lupus erythematosus (SLE) based on levels of erythrocyte bound C4d (EC4d) and B cell C4d (BC4d); along with anti-nuclear antibodies (ANA) and double-stranded DNA antibodies (ds-DNA). AVISE Lupus provides rheumatologists and their patients with sensitive and specific results.
- Revenue in USD (TTM)55.73m
- Net income in USD-19.36m
- Incorporated2003
- Employees174.00
- LocationExagen Inc1261 Liberty Way Ste CVISTA 92081-8356United StatesUSA
- Phone+1 (760) 560-1501
- Fax+1 (302) 655-5049
- Websitehttps://exagen.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kindly MD Inc | 3.77m | -1.62m | 18.03m | 23.00 | -- | -- | -- | 4.79 | -0.2709 | -0.2709 | 0.6311 | -0.0182 | -- | -- | -- | 163,852.60 | -- | -- | -- | -- | 94.00 | -- | -42.92 | -- | 0.6799 | -29.02 | 1.40 | -- | -0.488 | -- | 36.34 | -- | -- | -- |
| Novo Integrated Sciences Inc | 13.66m | -12.08m | 20.01m | 127.00 | -- | 0.8399 | -- | 1.46 | -0.7517 | -0.7517 | 0.8584 | 1.25 | 0.3824 | 8.70 | 8.88 | 107,543.60 | -33.86 | -29.43 | -43.28 | -35.64 | 40.35 | 39.59 | -88.55 | -110.25 | 0.4089 | -3.98 | 0.1305 | -- | 7.11 | 7.17 | 59.77 | -- | -22.73 | -- |
| Pacific Green Technologies Inc | 89.10m | 7.88m | 20.41m | 45.00 | 2.67 | 1.24 | 2.56 | 0.2291 | 0.1458 | 0.1458 | 1.81 | 0.3154 | 1.99 | -- | 53.47 | 1,979,898.00 | 15.61 | -12.03 | 48.16 | -46.78 | 27.53 | 39.68 | 7.85 | -13.35 | -- | -0.6059 | 0.122 | -- | -50.52 | 30.80 | -5.25 | -- | -73.45 | -- |
| ATI Physical Therapy Inc | 713.56m | -119.67m | 20.92m | 6.00k | -- | -- | -- | 0.0293 | -28.91 | -28.91 | 171.81 | 25.33 | 0.7005 | -- | 7.81 | 118,926.00 | -5.34 | -- | -6.12 | -- | 15.64 | -- | -7.62 | -- | -- | -0.1011 | 0.8274 | -- | 9.97 | -- | 73.20 | -- | -- | -- |
| Concord Medical Services Hldgs Ltd (ADR) | 74.21m | -41.10m | 21.71m | 727.00 | -- | -- | -- | 0.2926 | -0.9409 | -0.9409 | 1.70 | -6.75 | 0.0891 | 9.81 | 5.27 | 102,079.00 | -8.81 | -9.49 | -85.81 | -39.24 | -14.26 | -15.06 | -98.81 | -134.56 | 0.2956 | -5.70 | 0.6348 | -- | 13.84 | 23.00 | 39.21 | -- | -6.88 | -- |
| Medirom Healthcare Technologies Inc(ADR) | 26.14m | -3.93m | 24.87m | 171.00 | -- | 18.99 | -- | 0.9513 | -0.9485 | -0.9485 | 5.88 | 0.2683 | 0.8847 | 406.62 | 10.40 | 152,892.80 | -13.29 | -- | -25.58 | -- | 17.03 | -- | -15.03 | -- | 0.3519 | -53.29 | 0.7856 | -- | -14.50 | -- | -3,210.30 | -- | -- | -- |
| Exagen Inc | 55.73m | -19.36m | 33.88m | 174.00 | -- | 1.69 | -- | 0.6079 | -1.09 | -1.09 | 3.13 | 1.15 | 0.8572 | -- | 5.52 | 320,304.60 | -29.78 | -30.21 | -34.58 | -33.75 | 58.76 | 54.86 | -34.74 | -55.36 | -- | -8.07 | 0.4998 | -- | 15.33 | 10.13 | 50.01 | -- | 33.00 | -- |
| Nutex Health Inc | 258.77m | -41.00m | 33.93m | 800.00 | -- | 0.5385 | -- | 0.1311 | -0.9175 | -0.9175 | 5.71 | 1.27 | 0.6203 | 67.70 | 4.41 | 323,463.30 | -8.88 | -69.35 | -10.70 | -84.85 | 15.49 | 10.97 | -14.32 | -102.85 | 1.63 | 0.2489 | 0.7617 | -- | 12.93 | 428.22 | 89.22 | -- | -- | -- |
| Oncology Institute Inc | 342.71m | -59.65m | 36.79m | 800.00 | -- | 0.8893 | -- | 0.1073 | -0.8066 | -0.8066 | 4.63 | 0.5557 | 1.56 | 26.16 | 6.55 | 428,391.30 | -33.23 | -- | -40.16 | -- | 16.76 | 19.54 | -21.29 | -9.99 | 2.83 | -7.94 | 0.6816 | -- | 28.42 | 23.43 | -99,919.12 | -- | 45.68 | -- |
| Holder | Shares | % Held |
|---|---|---|
| RTW Investments LPas of 31 Mar 2024 | 1.50m | 8.73% |
| Cowen & Co. LLCas of 31 Mar 2024 | 898.63k | 5.21% |
| Wasatch Advisors LPas of 31 Mar 2024 | 786.90k | 4.57% |
| Silvercrest Asset Management Group LLCas of 31 Mar 2024 | 544.88k | 3.16% |
| Perkins Capital Management, Inc.as of 31 Mar 2024 | 493.57k | 2.86% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 486.80k | 2.82% |
| Morgan Stanley & Co. LLCas of 31 Mar 2024 | 482.42k | 2.80% |
| Stonepine Capital Management LLCas of 31 Mar 2024 | 384.60k | 2.23% |
| Geode Capital Management LLCas of 31 Mar 2024 | 81.58k | 0.47% |
| Penbrook Management LLCas of 31 Mar 2024 | 76.71k | 0.45% |
